北京大学学报(医学版) ›› 2018, Vol. 50 ›› Issue (2): 326-330. doi: 10.3969/j.issn.1671-167X.2018.02.020

• 论著 • 上一篇    下一篇

MicroRNA-155靶向的放射性标记探针对乳腺癌小鼠模型的活体显像

康磊1*,霍焱1*,王荣福1△,张春丽1,闫平1,徐小洁2△   

  1. (1. 北京大学第一医院核医学科,北京100034; 2. 军事医学科学院生物工程研究所,北京100850)
  • 出版日期:2018-04-18 发布日期:2018-04-18
  • 通讯作者: 王荣福,徐小洁 E-mail: rongfu_wang@163.com, miraclexxj@126.com
  • 基金资助:
    国家自然科学基金(81101065、81071183)、高等学校博士学科点新教师专项科研基金(20110001120043)、首都临床特色应用研究(Z141107002514159)资助

In vivo imaging of breast tumors by a 99mTc radiolabeled probe targeting microRNA-155 in mice models

KANG Lei1*, HUO Yan1*, WANG Rong-fu1△, ZHANG Chun-li1, YAN Ping1, XU Xiao-jie2△   

  1. (1. Department of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China; 2. Department of Medical Molecular Biology, Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Beijing 100850, China)
  • Online:2018-04-18 Published:2018-04-18
  • Contact: WANG Rong-fu, XU Xiao-jie E-mail: rongfu_wang@163.com, miraclexxj@126.com
  • Supported by:
    Supported by the National Natural Science Foundation of China (81101065, 81071183), the Higher Education Doctoral Program of China Research Fund for New Teacher (20110001120043), and the Capital Foundation for Clinical Characteristics and Application Research (Z141107002514159)

摘要: 目的:microRNA-155(miR-155)显著高表达于乳腺癌、肺癌、肝癌等多种恶性肿瘤,本研究旨在构建靶向miR-155的放射性示踪探针对乳腺肿瘤的活体显像。方法:体外化学合成靶向miR-155的反义互补寡核苷酸探针(AMO-155),并对其进行5′端乙酰基修饰及2′甲氧基修饰,进而与双功能螯合剂NHSMAG3偶联后,在氯化亚锡的还原作用下对其标记 99mTc,评价血清稳定性,并对乳腺癌荷瘤裸鼠进行活体显像,对比反义、无义及阻断组的显像差异,并通过实时定量PCR(quantitative real-time PCR, qRT-PCR)鉴定肿瘤的miR-155水平。结果:99mTc-AMO-155的制备标记率达97%(n=5),放射化学纯度大于98%(n=5),放射比活度约为3.75 GBq/μg。通过对比无义对照组及阻断组,99mTc-AMO-155能够在活体水平特异性地显示miR-155高表达的恶性肿瘤。此外,针对miR-155不同表达水平的肿瘤,99mTc-AMO-155亦可在活体水平反映其表达差异。结论:经化学修饰的99mTc标记的AMO-155探针具有良好的血清稳定性及活体肿瘤靶向识别作用,为肿瘤显像提供了潜在的新型探针。

关键词: 微RNAs, 锝, 乳腺肿瘤, 寡核苷酸探针, 放射性核素显像, 小鼠,

Abstract: Objective: MicroRNA-155 (miR-155) is significantly highly expressed in breast cancer, lung cancer, liver cancer and other malignant tumors. This study was to design and construct a radiolabeled probe targeting miR-155 for in vivo imaging in breast cancer. Methods: Anti-miR-155 oligonu-cleotide (AMO-155) was chemically synthesized with 2′-OMe modification. Its 5′ end was linked with acetyl amine group. After chelated with a bifunctional chelator NHSMAG3, AMO155 was radiolabeled with 99mTc using stannous chloride. The serum stability was evaluated at cellular level. In vivo imaging was performed in MCF-7 tumor bearing mice after the administration of 99mTc radiolabeled AMO-155 and scramble control probes, respectively. Furthermore, the blocked imaging of tumor bearing mice was obtained after the injection of unlabeled AMO-155 2 hours ahead. MCF-7 and MDA-MB-231 tumor bearing mice with different expression level of miR-155 were imaged, respectively. Quantitative real-time PCR (qRT-PCR) was used to identify the expression level of miR-155 in the bearing tumors. Results: 99mTc-AMO-155 was prepared with high radiolabeled efficiency (97%), radiochemical purity (greater than 98%), and radioactive specific activity (3.75 GBq/μg). 99mTc-AMO-155 was stable in fresh human serum for 12 hours. After the administration via tail vein, 99mTc-AMO-155 displayed significant accumulation in MCF-7 bearing tumors with high expression level of miR-155, whereas 99mTc-control showed little accumulation. After blocked with unlabeled AMO-155, the tumor could not be visualized clearly after the administration of 99mTc-AMO-155. Furthermore, 99mTc-AMO-155 could show the differential expression of miR-155 in vivo. MCF-7 tumor was shown with significantly higher radioactive accumulation than MDA-MB-231, based on its higher expression level of miR-155, which was verified by qRT-PCR. Conclusion: 99mTc-labeled AMO-155 with chemical modification showed good serum stability and in vivo tumor targeting ability. This study provides a potential probe for in vivo imaging of breast cancer.

Key words: MicroRNA, Technetium, Breast neoplasms, Oligonucleotide probes, Radionuclide imaging, Mice, nude

中图分类号: 

  •  
[1] 李文根,古晓东,翁锐强,刘苏东,陈超. 血浆外泌体miR-34-5p和miR-142-3p在系统性硬化症中的表达及临床意义[J]. 北京大学学报(医学版), 2023, 55(6): 1022-1027.
[2] 马建勋,夏有辰,李比,赵红梅,雷玉涛,布希. 乳腺癌改良根治术后即刻乳房重建的方式选择[J]. 北京大学学报(医学版), 2023, 55(4): 612-618.
[3] 张云静,乔丽颖,祁萌,严颖,亢伟伟,刘国臻,王明远,席云峰,王胜锋. 乳腺癌患者新发心血管疾病预测模型的建立与验证:基于内蒙古区域医疗数据[J]. 北京大学学报(医学版), 2023, 55(3): 471-479.
[4] 袁婷婷,李燊,吴燕,吴海涛. 长期自由选择饮酒小鼠模型的建立及其行为学评价[J]. 北京大学学报(医学版), 2023, 55(2): 315-323.
[5] 张京,宋佳桂,王振斌,龚玉清,王天卓,周津羽,战军,张宏权. Kindlin-2通过mTOR和Hippo信号通路调节小鼠子宫内膜发育[J]. 北京大学学报(医学版), 2022, 54(5): 846-852.
[6] 王跃,张爽,张虹,梁丽,徐玲,程元甲,段学宁,刘荫华,李挺. 激素受体阳性/人表皮生长因子受体2阴性乳腺癌临床病理特征及预后[J]. 北京大学学报(医学版), 2022, 54(5): 853-862.
[7] 焦翠,王俭妹,况海霞,武志红,柳涛. CACNA1H基因敲除对小鼠孤独症样行为及海马神经元形态学的影响[J]. 北京大学学报(医学版), 2022, 54(2): 209-216.
[8] 贾睿璇,姜尚伟,赵琳,杨丽萍. Cyp4v3基因敲除小鼠模型的表型分析[J]. 北京大学学报(医学版), 2021, 53(6): 1099-1106.
[9] 朱忆颖,闵赛南,俞光岩. 局部注射环孢素A对非肥胖糖尿病小鼠下颌下腺分泌功能及炎症的影响[J]. 北京大学学报(医学版), 2021, 53(4): 750-757.
[10] 杨榕,李庆祥,王逸飞,周闻,王雯,郭传瑸,刘浩,郭玉兴. 碘液浸染在Micro-CT下识别小鼠颅底-颞下区肿瘤组织中的应用[J]. 北京大学学报(医学版), 2021, 53(3): 598-601.
[11] 王晓,贺丹,李文婷,阿迪拉·斯依提,韩蕊,董颖. 144例维吾尔族与汉族女性子宫内膜癌微小RNA表达特点及临床意义[J]. 北京大学学报(医学版), 2020, 52(3): 570-577.
[12] 朱梅青,崔蓉. 高效液相色谱法测定小鼠血浆中苯并三唑类紫外线吸收剂UV-327和UV-328[J]. 北京大学学报(医学版), 2020, 52(3): 591-596.
[13] 宋国红,李惠平,邸立军,严颖,姜晗昉,徐玲,万冬桂,李瑛,王墨培,肖宇,张如艳,冉然,王环. 真实世界吡咯替尼治疗HER2阳性转移性乳腺癌的疗效及安全性[J]. 北京大学学报(医学版), 2020, 52(2): 254-260.
[14] 张静,李素芳,陈红,宋俊贤. miR-106b-5p在调节内皮细胞基因表达谱中的作用[J]. 北京大学学报(医学版), 2019, 51(2): 221-227.
[15] 张晓威,殷华奇,李清,赵永平,KiteBrandes,白文俊,徐涛. 人类趋化素样因子超家族2参与小鼠精子形成[J]. 北京大学学报(医学版), 2019, 51(2): 228-233.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!